HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017 : A 10-Year Experience
Piron, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Salvador, Fernando (Hospital Universitari Vall d'Hebron)
Caballero Requero, Estrella (Hospital Universitari Vall d'Hebron)
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron)
Bes, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Casamitjana, Natàlia (Banc de Sang i Teixits de Catalunya)
Puig Sanz, Lluís (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Molina Romero, Israel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Sauleda, Silvia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Universitat Autònoma de Barcelona

Fecha:	2022
Resumen:	Human T-cell lymphotropic virus type 1 and 2 (HTLV-1/2) screening is not mandatory in Spanish blood banks. In Catalonia, selective screening was introduced in 2008, followed by universal screening in 2011. We present herein a 10-year experience of HTLV testing in blood donors. HTLV-1/2 selective screening was performed using Ortho-Clinical Diagnostics HTLV-I/HTLV-II Ab-Capture ELISA between February 2008 and May 2009, then Abbott Prism HTLV-I/ HTLV-II assay until December 2010. Abbott Architect rHTLV-I/II assay was then used for HTLV-1/2 universal screening in pooled samples. INNO-LIA HTLV I/II Score (Fujirebio) and in-house HTLV-1/2 proviral DNA real-time PCR were used in reactive samples. Follow-up was offered to confirm HTLV-1/2 donors in Vall d'Hebron Hospital. Between 2008 and 2017, 51 blood donors were confirmed HTLV positive (46 HTLV-1, 4 HTLV-2 and 1 HTLV) out of 2,114,891 blood donations (1 in 41,468). Sixty-nine percent were female, median age was 40 years and most were born in Latin America (69%), followed by Europe (25%), Africa (4%) and Asia (2%). Screening of relatives and partners identified 12 additional HTLV-1 cases. Lookback studies did not show any HTLV-1/2 transmission. HTLV infections found in blood donors mirror epidemiological changes in the population of Spain. Consequently, HTLV should be considered a potential risk for recipients and calls for the design of optimal strategies to ensure transfusion safety.
Ayudas:	Instituto de Salud Carlos III JE18/00022
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	HTLV-1/2 ; Screening ; Blood donors ; Leukoreduction ; Transfusion ; Spain
Publicado en:	Viruses, Vol. 14 (september 2022) , ISSN 1999-4915

DOI: 10.3390/v14091975
PMID: 36146780

12 p, 273.3 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados